# What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.

> **NCT02635230** · — · UNKNOWN · sponsor: **R&D Cardiologie** · enrollment: 2200 (estimated)

## Conditions studied

- Atrial Fibrillations
- Heart Valve Prostheses
- Acute Coronary Syndromes
- Coronary Artery Diseases
- Stroke
- Bleeding
- Myocardial Infarction

## Interventions

- **DRUG:** Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.

## Key facts

- **NCT ID:** NCT02635230
- **Lead sponsor:** R&D Cardiologie
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2021-01
- **Final completion:** 2022-01
- **Target enrollment:** 2200 (ESTIMATED)
- **Last updated:** 2020-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02635230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02635230, "What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02635230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*